These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 9435865)

  • 1. Lysis of murine B lymphoma cells by transgenic phagocytes via a human Fc gamma RI x murine MHC class II bispecific antibody.
    Heijnen IA; Glennie MJ; van de Winkel JG
    Cancer Immunol Immunother; 1997; 45(3-4):166-70. PubMed ID: 9435865
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HLA class II as potential target antigen on malignant B cells for therapy with bispecific antibodies in combination with granulocyte colony-stimulating factor.
    Elsässer D; Valerius T; Repp R; Weiner GJ; Deo Y; Kalden JR; van de Winkel JG; Stevenson GT; Glennie MJ; Gramatzki M
    Blood; 1996 May; 87(9):3803-12. PubMed ID: 8611706
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative efficiencies of bispecific F(ab'gamma)2 and chimeric mouse/human IgG antibodies in recruiting cellular effectors for cytotoxicity via Fc gamma receptors.
    Greenman J; Hogg N; Nikoletti S; Slade C; Stevenson G; Glennie M
    Cancer Immunol Immunother; 1992; 34(6):361-9. PubMed ID: 1532922
    [TBL] [Abstract][Full Text] [Related]  

  • 4. G-CSF-stimulated PMN in immunotherapy of breast cancer with a bispecific antibody to Fc gamma RI and to HER-2/neu (MDX-210).
    Repp R; Valerius T; Wieland G; Becker W; Steininger H; Deo Y; Helm G; Gramatzki M; Van de Winkel JG; Lang N
    J Hematother; 1995 Oct; 4(5):415-21. PubMed ID: 8581378
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Initial trial of bispecific antibody-mediated immunotherapy of CD15-bearing tumors: cytotoxicity of human tumor cells using a bispecific antibody comprised of anti-CD15 (MoAb PM81) and anti-CD64/Fc gamma RI (MoAb 32).
    Ball ED; Guyre PM; Mills L; Fisher J; Dinces NB; Fanger MW
    J Hematother; 1992; 1(1):85-94. PubMed ID: 1365020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A recombinant bispecific single-chain fragment variable specific for HLA class II and Fc alpha RI (CD89) recruits polymorphonuclear neutrophils for efficient lysis of malignant B lymphoid cells.
    Guettinger Y; Barbin K; Peipp M; Bruenke J; Dechant M; Horner H; Thierschmidt D; Valerius T; Repp R; Fey GH; Stockmeyer B
    J Immunol; 2010 Feb; 184(3):1210-7. PubMed ID: 20042573
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluating antibodies for their capacity to induce cell-mediated lysis of malignant B cells.
    Würflein D; Dechant M; Stockmeyer B; Tutt AL; Hu P; Repp R; Kalden JR; van de Winkel JG; Epstein AL; Valerius T; Glennie M; Gramatzki M
    Cancer Res; 1998 Jul; 58(14):3051-8. PubMed ID: 9679970
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bispecific-armed, interferon gamma-primed macrophage-mediated phagocytosis of malignant non-Hodgkin's lymphoma.
    Ely P; Wallace PK; Givan AL; Graziano RF; Guyre PM; Fanger MW
    Blood; 1996 May; 87(9):3813-21. PubMed ID: 8611707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Triggering Fc alpha-receptor I (CD89) recruits neutrophils as effector cells for CD20-directed antibody therapy.
    Stockmeyer B; Dechant M; van Egmond M; Tutt AL; Sundarapandiyan K; Graziano RF; Repp R; Kalden JR; Gramatzki M; Glennie MJ; van de Winkel JG; Valerius T
    J Immunol; 2000 Nov; 165(10):5954-61. PubMed ID: 11067958
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bispecific Ab therapy of B-cell lymphoma: target cell specificity of antibody derivatives appears critical in determining therapeutic outcome.
    Honeychurch J; Cruise A; Tutt AL; Glennie MJ
    Cancer Immunol Immunother; 1997; 45(3-4):171-3. PubMed ID: 9435866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic efficacy of FcgammaRI/CD64-directed bispecific antibodies in B-cell lymphoma.
    Honeychurch J; Tutt AL; Valerius T; Heijnen IA; Van De Winkel JG; Glennie MJ
    Blood; 2000 Nov; 96(10):3544-52. PubMed ID: 11071653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro killing of neuroblastoma cells by neutrophils derived from granulocyte colony-stimulating factor-treated cancer patients using an anti-disialoganglioside/anti-Fc gamma RI bispecific antibody.
    Michon J; Moutel S; Barbet J; Romet-Lemonne JL; Deo YM; Fridman WH; Teillaud JL
    Blood; 1995 Aug; 86(3):1124-30. PubMed ID: 7542496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of a new monoclonal anti-Fc gamma RII antibody, AT10, and its incorporation into a bispecific F(ab')2 derivative for recruitment of cytotoxic effectors.
    Greenman J; Tutt AL; George AJ; Pulford KA; Stevenson GT; Glennie MJ
    Mol Immunol; 1991 Nov; 28(11):1243-54. PubMed ID: 1835758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A human Fc gamma RI/CD64 transgenic model for in vivo analysis of (bispecific) antibody therapeutics.
    Heijnen IA; Van de Winkel JG
    J Hematother; 1995 Oct; 4(5):351-6. PubMed ID: 8581368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bispecific molecules directed to the Fc receptor for IgA (Fc alpha RI, CD89) and tumor antigens efficiently promote cell-mediated cytotoxicity of tumor targets in whole blood.
    Deo YM; Sundarapandiyan K; Keler T; Wallace PK; Graziano RF
    J Immunol; 1998 Feb; 160(4):1677-86. PubMed ID: 9469424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FcalphaRI (CD89) as a novel trigger molecule for bispecific antibody therapy.
    Valerius T; Stockmeyer B; van Spriel AB; Graziano RF; van den Herik-Oudijk IE; Repp R; Deo YM; Lund J; Kalden JR; Gramatzki M; van de Winkel JG
    Blood; 1997 Dec; 90(11):4485-92. PubMed ID: 9373259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neutrophils express the high affinity receptor for IgG (Fc gamma RI, CD64) after in vivo application of recombinant human granulocyte colony-stimulating factor.
    Repp R; Valerius T; Sendler A; Gramatzki M; Iro H; Kalden JR; Platzer E
    Blood; 1991 Aug; 78(4):885-9. PubMed ID: 1714327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical studies with Fc(gamma)R bispecific antibodies and granulocyte colony-stimulating factor-primed neutrophils as effector cells against HER-2/neu overexpressing breast cancer.
    Stockmeyer B; Valerius T; Repp R; Heijnen IA; Bühring HJ; Deo YM; Kalden JR; Gramatzki M; van de Winkel JG
    Cancer Res; 1997 Feb; 57(4):696-701. PubMed ID: 9044847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the ability of red cells sensitized with a bispecific anti-D x anti-Fc gamma RIII Fab fragment to activate human K cells and peritoneal macrophages through Fc gamma RIII.
    Bakács T; Hadley AG; Kumpel BM; Segal DM; Banhidy F
    Immunol Lett; 1994 Sep; 42(1-2):91-5. PubMed ID: 7829136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential effect of cytokine treatment on Fc alpha receptor I- and Fc gamma receptor I-mediated tumor cytotoxicity by monocyte-derived macrophages.
    Keler T; Wallace PK; Vitale LA; Russoniello C; Sundarapandiyan K; Graziano RF; Deo YM
    J Immunol; 2000 Jun; 164(11):5746-52. PubMed ID: 10820252
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.